home
portfolio
approach
team
careers
news
contact
investor portal
home
portfolio
approach
team
careers
news
contact
investor portal
Nextech Invest
Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667
Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667
Post navigation
Previous Post
Previous
Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results
Next Post
Next
Blueprint Medicines to Present on BLU-285 and BLU-554 at Upcoming Scientific Conferences